Chief Quality Operations Officer and Executive Vice President, Translational Sciences
John Pinion has over 25 years of global experience providing executive leadership and expertise in engineering, quality, manufacturing management of biologic, pharmaceutical and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. Mr. Pinion provides leadership for Ultragenyx’s translational sciences functions to include Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance, Validation, and CMC Analytical Development and QC.
As a key member of Ultragenyx’s executive leadership team reporting directly to the organization’s CEO, he also contributes to ongoing business development, clinical development and commercial and strategic planning activities.
In the ten years prior to joining Ultragenyx, Mr. Pinion held roles of increasing responsibility at Genentech (subsequently Roche when Genentech was acquired), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland.
Previous to Genentech, Mr. Pinion spent 17 years in operational and senior leadership roles in Baxter International’s Renal, Bioscience, Parenterals and Device divisions.
John currently sits on the Board of Directors and serves as the Chair of the Audit and Risk Committee of Aroa Biosurgery Ltd, a privately-held soft tissue repair company commercializing regenerative tissue substitutes based in Auckland, New Zealand. He holds a B.S. in Mechanical Engineering from West Virginia University and lives in Northern California with his wife and two sons.